Peptide Therapy: The Complete 2026 Guide

Key takeaways

• Peptide therapy, done properly, is a licensed clinician prescribing an approved or legally compounded peptide after an evaluation with labs, then measuring whether it worked. Anything without those pieces is self-experimentation with an unlabeled vial.
• The evidence is uneven by goal: GLP-1 drugs for weight (strong), tesamorelin for visceral fat (good, but studied in people with HIV), sermorelin for growth hormone output (small 1990s trials), bremelanotide for low desire in premenopausal women (approved), NAD+ and glutathione (weak), BPC-157 and TB-500 (no human trials).
• The legal line in October 2026: sermorelin, PT-141, glutathione and NAD+ can be prescribed and compounded; tesamorelin can be prescribed only as the brand Egrifta; semaglutide and tirzepatide only within limits; BPC-157, TB-500, CJC-1295, ipamorelin and MOTS-c cannot be compounded by any pharmacy, whatever a website says.
• Expect $150 to $450 a month including the clinician, plus $100 to $400 in labs and consults in the first month. Compounded peptides are cash-pay.
• The questions that separate a clinic from a storefront: which pharmacy, on what legal basis, what labs before and after, what dose and in what units, and when do we stop.

If you have read what peptides are, you know the word covers approved drugs, compounded drugs, unregulated vials and skincare, and that the evidence runs from the best trials in modern medicine to none. This guide is about the process: what a competent course of peptide therapy looks like from the first conversation to the decision to stop, in the United States, under the rules that apply in October 2026.

What peptide therapy is, and what it is not

Peptide therapy is the prescription of a peptide drug by a licensed clinician for a defined goal, dispensed by a licensed pharmacy or a manufacturer, with monitoring. That definition does three jobs. It excludes supplements and creams, which are not therapy in any clinical sense. It excludes research vials bought online, which may contain the right molecule but come with no label, no pharmacist and no one to call. And it sets a standard that a legitimate telehealth clinic can meet in a week and an aggressive storefront cannot meet at all.

It is also worth saying what peptide therapy is not in 2026. It is not a specialty; there is no board certification in peptides, and the clinicians who prescribe them are family physicians, nurse practitioners, endocrinologists and urologists working from the same evidence you can read here. It is not a single protocol; the compounds have nothing in common except their chemistry. And it is not an alternative to medicine. The peptides with real effects are drugs, with drug side effects and drug interactions.

The goals people come with, and what has evidence for each

Almost everyone arrives with one of six goals. For each, the table grades the human evidence for the compound a US clinician can actually prescribe, using the A to D scale from our editorial policy.

Evidence by goal for peptides prescribed in the US, October 2026

Claim	Grade	What the evidence shows	Sources
Weight loss: semaglutide 2.4 mg weekly	A	STEP 1: 14.9% mean weight loss versus 2.4% with placebo at 68 weeks in 1,961 adults with obesity. Nausea, diarrhea, vomiting and constipation were the common side effects. FDA-approved (Wegovy).	Wilding 2021
Weight loss: tirzepatide 5 to 15 mg weekly	A	SURMOUNT-1: 15.0%, 19.5% and 20.9% mean weight loss at 5, 10 and 15 mg versus 3.1% with placebo at 72 weeks in 2,539 adults; gastrointestinal effects were mostly mild to moderate and clustered during dose escalation. FDA-approved (Zepbound).	Jastreboff 2022
Visceral fat: tesamorelin 2 mg daily	B	In 412 adults with HIV and abdominal fat accumulation, visceral fat fell 15.2% over 26 weeks versus a 5.0% rise with placebo; triglycerides fell and IGF-1 rose 81%. A 2026 meta-analysis of five trials confirms the visceral and liver-fat effect. Use in people without HIV is extrapolation.	Falutz 2007; Badran 2026
Growth hormone and IGF-1: sermorelin	B	In 10 healthy men aged about 68, GHRH(1-29) 1 mg twice daily for 14 days restored 24-hour GH and IGF-1 to young-adult levels; 0.5 mg did not. The trials are small, short and decades old, and used doses well above typical telehealth prescriptions.	Corpas 1992
Muscle, strength and body composition in healthy older adults via the GH axis	C	The best data are for growth hormone itself: about 2 kg less fat and 2 kg more lean mass, no demonstrated functional benefit, and more edema, joint pain, carpal tunnel syndrome and impaired fasting glucose. No sermorelin trial has measured strength adequately.	Liu 2007
Low sexual desire: bremelanotide (PT-141)	A	Two phase 3 trials in 1,267 premenopausal women with hypoactive sexual desire disorder: 1.75 mg as needed for 24 weeks raised the desire score by 0.35 points more than placebo and reduced distress; nausea, flushing and headache occurred in 10% or more. Approved only for that population; data in men are small.	Kingsberg 2019; Vyleesi label
Energy and longevity: NAD+ injections or infusions	C	The only human data on infused NAD+ is a pharmacokinetic pilot: during a 6-hour intravenous infusion, plasma NAD+ did not change for two hours and metabolites appeared in urine. No trial has measured energy, cognition or aging outcomes with injected NAD+.	Grant 2019
Skin lightening and detox: glutathione injections	C	A 2026 critical review found only small studies with modest, inconsistent pigmentation changes, usually with vitamin C co-administered, and raised liver toxicity, hypersensitivity and possible kidney and endocrine concerns with the intravenous route. No evidence for detox claims.	Aloraini 2026
Injury recovery and healing: BPC-157, TB-500	D	FDA reviewers told the July 2026 advisory committee there were no adequate human data for BPC-157 and no studies at all of TB-500 itself, with immunogenicity and product-characterization concerns. The committee voted 8 to 6 to recommend each anyway; FDA has not acted. No pharmacy may compound them.	HPM 2026a

What the table means in practice, goal by goal:

• Weight and metabolic health. The honest first choice is a GLP-1 drug, brand or compounded within the legal limits, and the question is which one and how to pay for it. Read the compounded semaglutide versus tirzepatide comparison and the weight-loss guide. Tesamorelin is a second-line option for stubborn visceral fat in someone who is not obese; its profile explains the HIV caveat.
• Muscle, recovery and body composition. Nothing a clinician can prescribe builds muscle the way the marketing suggests. Sermorelin raises growth hormone output; whether that changes your body is unproven at the doses clinics use. The muscle-growth guide ranks the options and explains why testosterone, not a peptide, is usually the real answer for a man with a documented deficiency.
• Longevity. No peptide has been shown to extend healthspan in humans. NAD+ and glutathione are legal to compound and weak in evidence; the longevity guide is mostly a guide to what not to pay for.
• Sexual function. PT-141 is an approved drug for one indication and a compounded off-label prescription for others.
• Skin and hair. Topical peptides are cosmetics; injectable GHK-Cu cannot be compounded; glutathione injections for skin lightening rest on small studies with safety signals.
• Women specifically. Hormone therapy has far more evidence than any peptide for menopausal symptoms; the women's guide covers where peptides fit beside it.

Step 1: the evaluation

A prescription for any of these drugs should follow an evaluation that would satisfy a careful primary-care physician. In telehealth that means a structured history, a medication list, a conversation about what you expect and labs before the first vial ships.

History and contraindications

The history has two purposes: to match the goal to a compound with evidence, and to find the reasons not to prescribe. The reasons differ by class.

A clinic that does not ask about cancer history before prescribing a growth hormone secretagogue, or about thyroid cancer in the family before a GLP-1, has skipped the only part of the visit that protects you.

Labs by goal

Labs do two things: they establish a baseline against which to judge the drug, and they catch the contraindications the history missed. What gets ordered should follow the goal.

Labs cost $100 to $400 cash in the first month, and some programs skip them for the cheaper compounds. For NAD+ or glutathione that is defensible, since no lab predicts a response. For a GLP-1 in someone who has never had an A1c, or for sermorelin without an IGF-1, it is not.

Step 2: the prescription and the pharmacy

Once a clinician decides a compound is appropriate, a prescription goes to one of three places: a manufacturer's pharmacy program (brand GLP-1 pens), a 503A compounding pharmacy or a 503B outsourcing facility. The difference matters.

503A pharmacies are state-licensed pharmacies that prepare a drug for a specific patient on a specific prescription. A pharmacist compounds it, the state board inspects the pharmacy, and the product carries a beyond-use date rather than an expiration date. 503B outsourcing facilities register with FDA, follow manufacturing standards closer to a drug company's, are inspected by FDA, and may produce batches without patient-specific prescriptions for clinic use. Neither makes an FDA-approved product; FDA's own summary is that compounded drugs have not been evaluated for safety, effectiveness or quality (FDA compounding Q&A). What the 503B route buys is batch testing and federal inspection; what the 503A route buys is a prescription-specific preparation at lower cost. Most telehealth peptide prescriptions in 2026 are filled by 503A pharmacies, and the better providers name theirs.

What a legitimate label looks like

The vial or pen that arrives should carry a label from the dispensing pharmacy, not from the telehealth brand. In March and June 2026 FDA sent 55 warning letters to telehealth companies partly because product images showed the company's own name on the label as if it were the manufacturer; our legal tracker has the dates. A proper compounded-drug label shows:

• the pharmacy's name, address and phone number;
• your name and the prescriber's name;
• the drug name and the strength as a concentration (for example, milligrams per milliliter), and the total quantity in the vial;
• directions in a unit you can measure (milligrams, and the volume or syringe units that corresponds to);
• a beyond-use date, lot number and storage instructions;
• a statement that it is a compounded drug.

If the label gives a strength but the instructions are in "units" with no conversion, use our units guide and ask the pharmacist to confirm before the first injection. A poison-center case series described patients who took ten times the intended dose of compounded semaglutide because they were dosing in milliliters or syringe units rather than milligrams, with vomiting and abdominal pain lasting days (Lambson 2023).

Step 3: what a course looks like

Two things the table makes obvious. First, for the compounds with good evidence, the course is long: months of escalation and a year or more of treatment for a GLP-1, six months for tesamorelin. A one-month trial of either tells you about side effects, not benefit. Second, for sermorelin, the dose gap between the literature and the typical prescription is large enough that a clinician who prescribes it should be able to say what dose they expect to move your IGF-1 and when they will check.

Injection technique and reconstitution are the same for every subcutaneous peptide; our injection guide and reconstitution guide cover them, and the reconstitution calculator turns a vial size and a dose into syringe units.

Step 4: monitoring, and when to stop

Monitoring is where a treatment differs from a subscription. The plan should be written down before the first dose, with a date and a number.

• GLP-1s. Weight and side effects at each dose step; A1c and lipids at 3 to 6 months if they were abnormal. Stop and seek care for severe abdominal pain (pancreatitis or gallbladder), persistent vomiting or signs of dehydration. Slow or pause escalation when nausea is limiting; in the trials, most gastrointestinal effects came during escalation and faded (Jastreboff 2022).
• Sermorelin and tesamorelin. IGF-1 and glucose at 8 to 12 weeks, then every 3 to 6 months. Stop if IGF-1 rises above the reference range, if fluid retention, joint pain or carpal tunnel symptoms appear, if glucose climbs, or if IGF-1 has not moved after three months of a dose the clinician expected to work. In the growth-hormone literature the side effects of pushing IGF-1 too high are well documented (Liu 2007).
• Bremelanotide. Blood pressure, and a reassessment at 8 weeks; the label says to stop if there is no improvement by then (Vyleesi label). Watch for darkening of the skin on the face, gums or breasts, which can persist.
• NAD+ and glutathione. There is no biomarker. The honest approach is a defined trial, usually 8 to 12 weeks, against a symptom you wrote down at the start, and stopping if it did not change. Injection-site reactions and, for glutathione, any rash or jaundice should end the course.
• Testosterone alongside. Testosterone and hematocrit at 3 to 6 months, then annually, with PSA according to age and risk (Bhasin 2018).

The general stop rules are simple. Stop if the goal was reached and the drug has no maintenance role. Stop if a measured endpoint did not move in the window the evidence predicts. Stop if a side effect outweighs a benefit you can name. And stop any compound the moment you learn no pharmacy can legally make it, because the vial you are holding did not come from one.

Side effects by class

• GLP-1 and GLP-1/GIP drugs: nausea, vomiting, diarrhea and constipation are common and usually transient; gallbladder disease, pancreatitis, slowed stomach emptying (relevant before anesthesia) and, for compounded vials, dosing errors because the product has none of the safety features of a pen (Wilding 2021; Lambson 2023). Rapid weight loss also costs lean mass, which is why resistance exercise and protein belong in every GLP-1 plan.
• GHRH analogs: injection-site reactions, flushing, headache, dizziness and nausea for sermorelin; for tesamorelin the pooled trial data add joint and muscle pain, tingling and injection-site redness (Badran 2026). Both raise IGF-1, which brings the growth hormone risks: edema, carpal tunnel syndrome, higher fasting glucose and a theoretical cancer concern (Liu 2007; Renehan 2004).
• Melanocortin agonist (bremelanotide): nausea in a large share of users, flushing, headache, a transient rise in blood pressure after each dose, and focal darkening of the skin with repeated use (Kingsberg 2019; Vyleesi label).
• NAD+: no controlled safety data for injections; clinics report flushing and nausea with rapid infusion, which is why intravenous NAD+ is given slowly.
• Glutathione: hypersensitivity reactions and liver toxicity have been reported with intravenous use, and the review that catalogued them concluded the evidence does not justify routine cosmetic use (Aloraini 2026).
• Unregulated "healing" peptides: the risks are unknown by definition. FDA's reviewers cited immunogenicity and, for TB-500, products whose sequence and molecular weight vary by vendor (HPM 2026a).

What it costs

Most telehealth peptide programs charge $150 to $450 a month with the medication included, and the first month adds a consultation ($0 to $200) and labs ($100 to $400). Brand GLP-1 pens cost $299 to $449 a month through the manufacturer cash programs; compounded semaglutide and tirzepatide run roughly $150 to $350; sermorelin, NAD+ and PT-141 cluster around $150 to $350 each. Compounded peptides are cash-pay, though prescriptions and clinician visits usually qualify for HSA and FSA money. The cost guide has October 2026 prices by compound, the provider pricing models, and the seven questions to ask before paying.

Is it legal?

Short version: peptides are not controlled substances, so possessing them is not a crime; prescribing is legal when the compound is an approved drug or one a pharmacy may legally compound; and selling an unapproved drug for human use is illegal regardless of a research-use label. As of October 2026 a licensed pharmacy may compound sermorelin, bremelanotide, glutathione and NAD+, and may compound semaglutide and tirzepatide only for a patient with a documented need the approved product cannot meet. Tesamorelin is an approved drug but also a biological product, so it is available only as the brand Egrifta and cannot be compounded at all. BPC-157, TB-500, KPV, MOTS-c, epitalon and semax were recommended by FDA's advisory committee in July 2026 and remain non-compoundable until FDA completes rulemaking; CJC-1295 and ipamorelin were voted down in 2024. The legal tracker carries the full table, the 2026 timeline and the changelog, and is the page to check before any purchase.

How telehealth works for peptides

Telehealth is the way most Americans now get peptides prescribed, and the model is worth understanding.

Licensing. The practice of medicine happens where the patient is. The clinician who prescribes must hold a license in the state you are physically in during the visit, which is why national platforms publish state lists and why a provider that "serves all 50 states" is really a network of clinicians with different licenses.

Synchronous versus asynchronous visits. A synchronous visit is live: video or phone with the clinician. An asynchronous visit is a questionnaire the clinician reviews later, followed by messaging. Because peptides are not controlled substances, federal law does not require a live visit, but several states do for a first prescription; state rules differ, and our state-by-state guide lists the ones we verified; some providers go further as a matter of policy, and one in our clinic directory requires a brief live visit in Arkansas, Kansas, Mississippi, Missouri, New Mexico, North Dakota, Oregon, West Virginia and the District of Columbia. Asynchronous care is cheaper and faster; it is also where the evaluation gets thinnest. For a GLP-1 or a GHRH analog, insist on at least one live conversation and a lab review.

Who is actually treating you. Many platforms are technology companies that contract with independent medical groups; the website is the brand, the prescriber is a licensed clinician in a separate practice, and the pharmacy is a third party. That structure is legal and common. It becomes a problem when none of the three will put a name on the label, the prescription or the follow-up.

The pharmacy and shipping. Compounded peptides ship cold from the pharmacy, usually within a week of approval. Some states restrict which compounded products may be shipped in, which is the usual reason a compound is "not available in your state."

Red flags, and the questions to ask

Red flags, in rough order of seriousness:

1. A peptide no pharmacy may compound, sold as "prescription" or "legal." BPC-157, TB-500, CJC-1295, ipamorelin, MOTS-c, epitalon, AOD-9604. The product is a research vial with a consultation stapled to it.
2. No pharmacy named, or the telehealth brand's own name on the label.
3. No labs for a GLP-1 or a growth hormone secretagogue, or no plan to repeat them.
4. A shopping cart instead of an evaluation: no history taken, no contraindications asked, approval in minutes for every applicant.
5. Doses in units with no concentration, or a dose chart copied from a research-chemical site.
6. Promises: specific pounds, "reversed aging," guaranteed IGF-1 numbers, before-and-after photos as evidence.
7. Stacks of four or five compounds at once, which make it impossible to know what caused a benefit or a side effect.
8. Pricing that hides the second month: a $99 starting price that becomes $300 at the maintenance dose, plus a membership fee.

The questions, which a good clinic answers in a minute:

• Which pharmacy will fill this, in which state, and is it a 503A pharmacy or a 503B outsourcing facility?
• On what legal basis is this compound compoundable right now?
• What labs will you order before and after, and what result would make you stop?
• What is the dose in milligrams, the concentration in the vial, and the syringe units that corresponds to?
• Will I speak to the same clinician, and how do I reach someone about a side effect?
• What is the total for the first three months, including labs, visits, shipping and any membership?

Realistic timelines

Bottom line

Peptide therapy done properly is unremarkable medicine: a goal, a compound with evidence for it, an evaluation that looks for reasons to say no, labs before and after, a labeled product from a licensed pharmacy, a dose you can verify, and a date on which you decide whether it worked. The compounds that meet that standard in 2026 are the GLP-1 drugs, tesamorelin, sermorelin, bremelanotide and, with weak evidence, NAD+ and glutathione. The ones that cannot meet it, because no pharmacy may make them, are the ones with the loudest marketing. If a provider can answer the six questions above without flinching, you are probably in the right place. If they cannot, the price does not matter.

Frequently asked questions

+−Who qualifies for peptide therapy?

It depends on the compound, because each has its own indication and its own exclusions. GLP-1 drugs are approved for adults with obesity (BMI 30 or more) or overweight (BMI 27 or more) with a weight-related condition, and are contraindicated with a personal or family history of medullary thyroid cancer or MEN 2. Sermorelin and tesamorelin are usually prescribed to adults with symptoms and a low or low-normal IGF-1, and avoided in anyone with an active cancer. Bremelanotide is approved for premenopausal women with hypoactive sexual desire disorder and should not be used with uncontrolled high blood pressure. A clinician who prescribes without asking about these things is not qualifying you; they are selling to you.

+−Can telehealth prescribe peptides?

Yes, for approved peptide drugs, including brand tesamorelin (Egrifta), which cannot be compounded, and for the peptides a licensed pharmacy can legally prepare: sermorelin, bremelanotide (PT-141), glutathione, NAD+ and, within limits, semaglutide and tirzepatide. The clinician must hold a license in the state where you are located during the visit, and a few states require a live audio or video visit before a first prescription. No telehealth service can legally prescribe BPC-157, TB-500, CJC-1295, ipamorelin or MOTS-c in October 2026, because no pharmacy may compound them; a site offering a 'prescription' for those is shipping research vials.

+−How often should you do peptide therapy?

The frequency comes from the compound, not from a program. Semaglutide and tirzepatide are injected once a week. Sermorelin and tesamorelin were studied as daily injections, usually at bedtime. Bremelanotide is used as needed before sexual activity, no more than once in 24 hours and eight times a month. NAD+ and glutathione have no trial-based schedule at all, so any 'protocol' you are given for them is the clinic's habit, not evidence.

+−How long is peptide therapy?

Long enough to see the measured outcome, then as long as the benefit justifies the cost and the side effects. The GLP-1 trials ran 68 to 72 weeks and weight returns when the drug stops. The tesamorelin trial ran 26 weeks. Sermorelin raised IGF-1 within two weeks at trial doses, so a clinician should know within 8 to 12 weeks whether it is doing anything. Bremelanotide's label says to stop after 8 weeks if nothing has improved. A course with no stop rule is a subscription, not a treatment.

+−What are the negative side effects of peptide injections?

They differ by class. GLP-1 drugs cause nausea, vomiting, diarrhea and constipation in a large minority of users and carry gallbladder and pancreatitis warnings. GHRH analogs cause injection-site reactions, flushing and headache, and raising IGF-1 brings the growth hormone risks: fluid retention, joint pain, carpal tunnel symptoms and higher glucose. Bremelanotide causes nausea in a large share of users, plus flushing, headache and a temporary rise in blood pressure. Glutathione infusions have been linked to liver toxicity and allergic reactions. Unregulated vials add a different risk: nobody knows what is in them.

+−Is peptide therapy covered by insurance?

Compounded peptides almost never are; you pay cash, usually $150 to $450 a month including the clinician. Brand GLP-1 drugs may be covered for obesity or diabetes depending on the plan, and the manufacturer cash programs now price Wegovy and Zepbound at $299 to $449 a month. Prescribed medications and the visits to obtain them generally qualify for HSA and FSA money.

+−What are the top 3 peptides to take?

There is no top three that applies to everyone, but there is a ranking by evidence. For weight, semaglutide and tirzepatide have the strongest trials in modern medicine. For visceral fat, tesamorelin has randomized data, though only in people with HIV. For sexual desire in premenopausal women, bremelanotide is an approved drug with two phase 3 trials. Everything marketed for healing, longevity and 'anti-aging' sits far below those, and the loudest ones (BPC-157, TB-500) have no human trials at all.

+−Can you get prescribed peptides online?

Yes, and the directory linked from this guide compares twelve US telehealth providers on what they offer, what they charge, which states they serve, whether they name their pharmacy and whether they require labs. The important check is whether the compound you want can be legally compounded; if it cannot, the online 'prescription' is theater.

+−Can I get a BPC-157 prescription online?

Not a real one. As of October 2026 BPC-157 is not FDA-approved, is not on FDA's list of substances pharmacies may compound, and has no USP monograph, so no licensed pharmacy may make it. FDA's advisory committee voted 8 to 6 in July 2026 to recommend adding it, over the objection of FDA's own reviewers, and FDA has not acted. A website that sells it with a consultation attached is selling a research vial.

Sources

1. StudyWilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989-1002. (2021)
2. StudyJastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387:205-16. (2022)
3. StudyFalutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007;357:2359-70. (2007)
4. ReviewBadran AS et al. Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin in HIV-associated lipodystrophy: a meta-analysis of randomized controlled trials. Obes Res Clin Pract 2026;20:2-12. (2026)
5. StudyCorpas E et al. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and IGF-I levels in old men. J Clin Endocrinol Metab 1992;75:530-5. (1992)
6. ReviewLiu H et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 2007;146:104-15. (2007)
7. StudyKingsberg SA et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials (RECONNECT). Obstet Gynecol 2019;134:899-908. (2019)
8. LabelCosette Pharmaceuticals. Vyleesi (bremelanotide) injection: prescribing information (dosing limits, blood pressure warning, 8-week reassessment, hyperpigmentation). Revised March 2024 (DailyMed version published November 2025). (2025)
9. LabelNovo Nordisk. Wegovy (semaglutide) injection: prescribing information (indication, dose escalation, contraindications, warnings). DailyMed.
10. StudyGrant R et al. A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6 hour intravenous infusion of NAD+. Front Aging Neurosci 2019;11:257. (2019)
11. ReviewAloraini K et al. Glutathione for skin lightening via intravenous, oral, and topical routes: a critical narrative review of current evidence, safety, and the evidence-practice gap. J Med Life 2026;19:511-23. (2026)
12. NewsPalmer KL, Snow CD, Bass M. PCAC approves four bulk drug substances for the 503A list (BPC-157, KPV, TB-500, MOTS-c). FDA Law Blog, Hyman Phelps & McNamara, July 24, 2026. (2026)
13. ReviewRenehan AG et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363:1346-53. (2004)
14. StudyLambson JE, Flegal SC, Johnson AR. Administration errors of compounded semaglutide reported to a poison control center: case series. J Am Pharm Assoc 2023;63:1643-5. (2023)
15. GuidelineBhasin S et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2018;103:1715-44. (2018)
16. RegulatoryFDA. Compounding and the FDA: questions and answers (503A pharmacies, 503B outsourcing facilities, why compounded drugs are not FDA-approved).